Le rapport
Analyses approfondies du financement des entreprises, des stratégies de croissance et des insights de marché des entreprises les plus innovantes du monde
5 rapports et plus encore
Corsera Health Raises $80M Series A | Once-Yearly Cardiovascular RNAi
Biotech startup Corsera Health secures $80 million Series A for once-yearly RNAi cardiovascular treatments.
Alnylam Pharmaceuticals raises $360M Convertible Note at $25B valuation
Alnylam Pharmaceuticals raises $360M in Convertible Note at $25B valuation. RNAi therapeutics...
Third Harmonic Bio raises $200M Series C at $750M valuation
Third Harmonic Bio raises $200M in Series C at $750M valuation. Dicerna-based RNAi therapeutics...
Alnylam Pharmaceuticals Raises $360M in Convertible Note
Alnylam Pharmaceuticals, a Biotech company based in 675 West Kendall Street, Cambridge, MA 02142, has raised $360M in Convertible Note at a $25B valuation led by Millennium Partners, Polaris Partners, Temasek Holdings.
Third Harmonic Bio Raises $200M in Series C
Third Harmonic Bio, a Biotech company based in 325 Vassar Street, Cambridge, MA 02139, has raised $200M in Series C at a $750M valuation led by ARCH Venture Partners, Polaris Partners, RA Capital Management, GV.
Affichage de 5 rapports • Page 1 • Catégorie : all
Restez en avance sur le marché
Recevez des insights hebdomadaires dans votre boîte de réception. Pas de spam, juste de l'intelligence.